199 related articles for article (PubMed ID: 38251379)
1. Myxoma Virus Combination Therapy Enhances Lenalidomide and Bortezomib Treatments for Multiple Myeloma.
Yeşilaltay A; Muz D; Erdal B; Bilgen T; Batar B; Turgut B; Topçu B; Yılmaz B; Avcı BA
Pathogens; 2024 Jan; 13(1):. PubMed ID: 38251379
[TBL] [Abstract][Full Text] [Related]
2. Transplantation of autologous bone marrow pre-loaded
Villa NY; Rahman MM; Mamola J; Sharik ME; de Matos AL; Kilbourne J; Lowe K; Daggett-Vondras J; D'Isabella J; Goras E; Chesi M; Bergsagel PL; McFadden G
Oncotarget; 2022; 13():490-504. PubMed ID: 35251496
[TBL] [Abstract][Full Text] [Related]
3. Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib.
Nijhof IS; Groen RW; Noort WA; van Kessel B; de Jong-Korlaar R; Bakker J; van Bueren JJ; Parren PW; Lokhorst HM; van de Donk NW; Martens AC; Mutis T
Clin Cancer Res; 2015 Jun; 21(12):2802-10. PubMed ID: 25398450
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of adding daratumumab or bortezomib to lenalidomide plus dexamethasone for newly diagnosed multiple myeloma.
Narsipur N; Bulla S; Yoo C; Do B; Tran K; Gu D; Zhong L; Wilson L
J Manag Care Spec Pharm; 2021 Dec; 27(12):1691-1702. PubMed ID: 34818089
[No Abstract] [Full Text] [Related]
5. Oncolytic
Yeşilaltay A; Muz D; Erdal B
Turk J Haematol; 2024 Mar; 41(1):16-25. PubMed ID: 38258554
[TBL] [Abstract][Full Text] [Related]
6. Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial.
Goldschmidt H; Mai EK; Bertsch U; Fenk R; Nievergall E; Tichy D; Besemer B; Dürig J; Schroers R; von Metzler I; Hänel M; Mann C; Asemissen AM; Heilmeier B; Weinhold N; Huhn S; Kriegsmann K; Luntz SP; Holderried TAW; Trautmann-Grill K; Gezer D; Klaiber-Hakimi M; Müller M; Khandanpour C; Knauf W; Scheid C; Munder M; Geer T; Riesenberg H; Thomalla J; Hoffmann M; Raab MS; Salwender HJ; Weisel KC;
Lancet Haematol; 2022 Nov; 9(11):e810-e821. PubMed ID: 36328040
[TBL] [Abstract][Full Text] [Related]
7. Treating brain tumor-initiating cells using a combination of myxoma virus and rapamycin.
Zemp FJ; Lun X; McKenzie BA; Zhou H; Maxwell L; Sun B; Kelly JJ; Stechishin O; Luchman A; Weiss S; Cairncross JG; Hamilton MG; Rabinovich BA; Rahman MM; Mohamed MR; Smallwood S; Senger DL; Bell J; McFadden G; Forsyth PA
Neuro Oncol; 2013 Jul; 15(7):904-20. PubMed ID: 23585629
[TBL] [Abstract][Full Text] [Related]
8. Autologous Transplantation Using Donor Leukocytes Loaded
Villa NY; Rahman MM; Mamola J; D'Isabella J; Goras E; Kilbourne J; Lowe K; Daggett-Vondras J; Torres L; Christie J; Appel N; Cox AL; Kim JB; McFadden G
Mol Ther Oncolytics; 2020 Sep; 18():171-188. PubMed ID: 32695875
[TBL] [Abstract][Full Text] [Related]
9. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.
Durie BGM; Hoering A; Abidi MH; Rajkumar SV; Epstein J; Kahanic SP; Thakuri M; Reu F; Reynolds CM; Sexton R; Orlowski RZ; Barlogie B; Dispenzieri A
Lancet; 2017 Feb; 389(10068):519-527. PubMed ID: 28017406
[TBL] [Abstract][Full Text] [Related]
10. Combination Lenalidomide/Bortezomib Treatment Synergistically Induces Calpain-Dependent Ikaros Cleavage and Apoptosis in Myeloma Cells.
Ganesan S; Palani HK; Balasundaram N; David S; Devasia AJ; George B; Mathews V
Mol Cancer Res; 2020 Apr; 18(4):529-536. PubMed ID: 31915234
[TBL] [Abstract][Full Text] [Related]
11. Apoptosis-inducing effect of myxoma virus on human neuroglioma cell lines.
Zhang QS; Zhang M; Huang XJ; Liu XJ; Li WP
Exp Ther Med; 2017 Jul; 14(1):344-348. PubMed ID: 28672936
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma.
Ocio EM; Vilanova D; Atadja P; Maiso P; Crusoe E; Fernández-Lázaro D; Garayoa M; San-Segundo L; Hernández-Iglesias T; de Alava E; Shao W; Yao YM; Pandiella A; San-Miguel JF
Haematologica; 2010 May; 95(5):794-803. PubMed ID: 19951978
[TBL] [Abstract][Full Text] [Related]
13. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
[TBL] [Abstract][Full Text] [Related]
14. Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma: The MANHATTAN Nonrandomized Clinical Trial.
Landgren O; Hultcrantz M; Diamond B; Lesokhin AM; Mailankody S; Hassoun H; Tan C; Shah UA; Lu SX; Salcedo M; Werner K; Rispoli J; Caple J; Sams A; Verducci D; Jones K; Concepcion I; Ciardello A; Chansakul A; Schlossman J; Tavitian E; Shekarkhand T; Harrison A; Piacentini C; Rustad EH; Yellapantula V; Maclaughlan K; Maura F; Landau HJ; Scordo M; Chung DJ; Shah G; Lahoud OB; Thoren K; Murata K; Ramanathan L; Arcila ME; Ho C; Roshal M; Dogan A; Derkach A; Giralt SA; Korde N
JAMA Oncol; 2021 Jun; 7(6):862-868. PubMed ID: 33856405
[TBL] [Abstract][Full Text] [Related]
15. Oncolytic myxoma virus synergizes with standard of care for treatment of glioblastoma multiforme.
Burton C; Das A; McDonald D; Vandergrift WA; Patel SJ; Cachia D; Bartee E
Oncolytic Virother; 2018; 7():107-116. PubMed ID: 30538967
[TBL] [Abstract][Full Text] [Related]
16. Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial.
Kumar SK; Jacobus SJ; Cohen AD; Weiss M; Callander N; Singh AK; Parker TL; Menter A; Yang X; Parsons B; Kumar P; Kapoor P; Rosenberg A; Zonder JA; Faber E; Lonial S; Anderson KC; Richardson PG; Orlowski RZ; Wagner LI; Rajkumar SV
Lancet Oncol; 2020 Oct; 21(10):1317-1330. PubMed ID: 32866432
[TBL] [Abstract][Full Text] [Related]
17. In vitro cytotoxicity of the novel antimyeloma agents perifosine, bortezomib and lenalidomide against different cell lines.
Schmidt-Hieber M; Dabrowski R; Weimann A; Aicher B; Lohneis P; Busse A; Thiel E; Blau IW
Invest New Drugs; 2012 Apr; 30(2):480-9. PubMed ID: 21080211
[TBL] [Abstract][Full Text] [Related]
18. Caspase-8: Friend or Foe in Bortezomib/Lenalidomide-Based Therapy for Myeloma.
Zhou L
Front Oncol; 2022; 12():861709. PubMed ID: 35321428
[TBL] [Abstract][Full Text] [Related]
19. Myxoma virus-mediated oncolysis of ascites-derived human ovarian cancer cells and spheroids is impacted by differential AKT activity.
Correa RJ; Komar M; Tong JG; Sivapragasam M; Rahman MM; McFadden G; Dimattia GE; Shepherd TG
Gynecol Oncol; 2012 May; 125(2):441-50. PubMed ID: 22306204
[TBL] [Abstract][Full Text] [Related]
20. Targeting gallbladder cancer: oncolytic virotherapy with myxoma virus is enhanced by rapamycin in vitro and further improved by hyaluronan in vivo.
Weng M; Gong W; Ma M; Chu B; Qin Y; Zhang M; Lun X; McFadden G; Forsyth P; Yang Y; Quan Z
Mol Cancer; 2014 Apr; 13():82. PubMed ID: 24725816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
